← Back to Search

Herbal Medicine

Chinese Herbal Medicine for COVID-19 (MACH19 Trial)

Phase 1
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial will study a herbal treatment for COVID-19 to see if it is safe and effective.

Who is the study for?
Adults over 18 with a recent COVID-19 diagnosis, not severe enough for hospitalization. Participants must be able to track and report their health daily, avoid certain substances like alcohol and dairy, and use contraception if applicable. Those with drug abuse history, severe symptoms or specific medical conditions like kidney disease, uncontrolled hypertension or liver disease are excluded.
What is being tested?
The trial is testing the safety of a Chinese herbal formula called modified Qing Fei Pai Du Tang (mQFPD) against placebo in treating mild-to-moderate COVID-19 at home. It's randomized and double-blind, meaning neither the researchers nor participants know who gets the real treatment.
What are the potential side effects?
Potential side effects aren't specified but could include typical reactions to herbal supplements such as digestive discomfort or allergic reactions. Close monitoring will help identify any unexpected side effects due to mQFPD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of the intervention
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary study objectives
C-reactive protein
D-dimer
Duration of viral illness
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: modified Qing Fei Pei Du TangExperimental Treatment1 Intervention
encapsulated modified Qing Fei Pai Du Tang
Group II: PlaceboPlacebo Group1 Intervention
Organic brown rice

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,180 Previous Clinical Trials
1,574,996 Total Patients Enrolled
Gordon Saxe, MDStudy Chair - University of California, Los Angeles
Regents of the University of California - UCSD Medical Group, UCSD Medical Center-Hillcrest
Michigan State University College Of Human Medicine (Medical School)
University Of Ma Medical Sch (Residency)

Media Library

mQFPD (Herbal Medicine) Clinical Trial Eligibility Overview. Trial Name: NCT04939415 — Phase 1
Coronavirus Research Study Groups: Placebo, modified Qing Fei Pei Du Tang
Coronavirus Clinical Trial 2023: mQFPD Highlights & Side Effects. Trial Name: NCT04939415 — Phase 1
mQFPD (Herbal Medicine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04939415 — Phase 1
~14 spots leftby Nov 2025